etrumadenant + zimberelimab

Etrumadenant + zimberelimab is an investigational **combination regimen** being studied primarily in metastatic colorectal cancer (mCRC). Etrumadenant is a **small molecule, dual antagonist of the adenosine A2a and A2b receptors**, designed to counteract adenosine-mediated immunosuppression in the tumor microenvironment and restore antitumor immune activity[1][3]. Zimberelimab is an **anti-PD-1 monoclonal antibody** that blocks the programmed cell death-1 (PD-1) pathway to increase immune-mediated cancer cell killing[1][3]. The regimen has been tested with FOLFOX chemotherapy and bevacizumab (EZFB) and demonstrated statistically and clinically significant improvements in overall survival and progression-free survival over regorafenib in third-line mCRC patients[1][3][4]. Both etrumadenant and zimberelimab are developed by Arcus Biosciences and Gilead Sciences and are not yet approved for any indication[1][3][4][5].